SHP099

• CAT Number: I002342
• CAS Number: 1801747-42-1
• Molecular Formula: C16H19Cl2N5
• Molecular Weight: 352.30
• Purity: ≥95%
• Synonyms: 6-(4-amino-4-methyl-1-piperidinyl)-3-(2,3-dichlorophenyl)-2-pyrazinamine
• Target: Metabolic Enzyme/Protease
• Solubility: DMSO: ≤ 6.4 mg/mL (Need ultrasonic)
• Storage: -20°C
• IUPAC Name: 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine
• InChI: InChI=1S/C16H19Cl2N5/c1-16(20)5-7-23(8-6-16)12-9-21-14(15(19)22-12)10-3-2-4-11(17)13(10)18/h2-4,9H,5-8,20H2,1H3,(H2,19,22)
• InChIKey: YGUFCDOEKKVKJK-UHFFFAOYSA-N
• SMILES: CC1(CCN(CC1)C2=CN=C(C(=N2)N)C3=C(C(=CC=C3)Cl)Cl)N

SHP099（Cat No.:I002342）is a selective small molecule inhibitor of SHP2 (Src homology 2-containing protein tyrosine phosphatase 2), an enzyme involved in various signaling pathways, including those related to cancer cell growth, survival, and immune response regulation. SHP2 is a key mediator of the RAS-MAPK pathway, which is frequently dysregulated in cancers. By inhibiting SHP2, SHP099 aims to block oncogenic signaling, inhibit tumor growth, and enhance the effectiveness of other cancer therapies, including immune checkpoint inhibitors. It is being investigated in clinical trials for the treatment of solid tumors and hematologic malignancies.

Reference

[1]. Ying-Nan P et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.